{"id":"fluconazole-capsule","safety":{"commonSideEffects":[{"rate":"13","effect":"Headache"},{"rate":"7","effect":"Nausea"},{"rate":"6","effect":"Abdominal pain"},{"rate":"5","effect":"Diarrhea"},{"rate":"2","effect":"Rash"},{"rate":"1-2","effect":"Elevated liver enzymes"},{"rate":"<1","effect":"Stevens-Johnson syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluconazole is a triazole antifungal that selectively binds to fungal cytochrome P450 enzymes, blocking the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. This disruption leads to increased membrane permeability and cell death. The drug has broad-spectrum activity against many Candida species, Cryptococcus, and other fungi.","oneSentence":"Fluconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:50.523Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Candidiasis (oropharyngeal, esophageal, vaginal, and systemic)"},{"name":"Cryptococcal meningitis"},{"name":"Fungal prophylaxis in immunocompromised patients"},{"name":"Other invasive fungal infections"}]},"trialDetails":[{"nctId":"NCT05434104","phase":"NA","title":"The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study","status":"NOT_YET_RECRUITING","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2026-03","conditions":"Bacterial Vaginosis, Candida Vaginal","enrollment":114},{"nctId":"NCT05421858","phase":"PHASE3","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.","status":"RECRUITING","sponsor":"Basilea Pharmaceutica","startDate":"2024-12-11","conditions":"Candidemia, Candidiasis, Invasive","enrollment":450},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT03828773","phase":"NA","title":"PTX3-targeted Antifungal Prophylaxis","status":"RECRUITING","sponsor":"Bochud Pierre-Yves","startDate":"2019-02-11","conditions":"Candidiasis, Fungal Infection, Acute Myeloid Leukemia","enrollment":410},{"nctId":"NCT06274554","phase":"PHASE3","title":"Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-10-04","conditions":"Crohn's Disease, Inflammatory Bowel Diseases","enrollment":120},{"nctId":"NCT06822166","phase":"PHASE1","title":"Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-12-04","conditions":"Interaction Drug Food","enrollment":68},{"nctId":"NCT06771063","phase":"PHASE2","title":"A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients","status":"RECRUITING","sponsor":"Cisen Pharmaceutical CO., LTD.","startDate":"2025-01-13","conditions":"Vaginitis","enrollment":108},{"nctId":"NCT03135106","phase":"PHASE1","title":"A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-04-14","conditions":"Healthy","enrollment":54},{"nctId":"NCT04551963","phase":"PHASE1","title":"Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-11-15","conditions":"B-cell Malignancies","enrollment":26},{"nctId":"NCT06107829","phase":"PHASE4","title":"Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities","status":"WITHDRAWN","sponsor":"Stephen Ruedrich","startDate":"2025-01","conditions":"Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities","enrollment":""},{"nctId":"NCT05657613","phase":"PHASE1","title":"Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2023-01-03","conditions":"Drug Interactions","enrollment":60},{"nctId":"NCT04495608","phase":"PHASE2","title":"Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fluconazole in Hypercalcicuric Patients With Increased 1.25(OH) 2D Levels","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2021-01-13","conditions":"Nephrolithiasis, Nephrocalcinosis, Hypercalciuria","enrollment":56},{"nctId":"NCT04038008","phase":"PHASE1","title":"Single Dose Crossover Comparative Bioavailability Study of Two Formulations of Fluconazole 200 mg in Healthy Adult Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2019-07-26","conditions":"Bioequivalence","enrollment":26},{"nctId":"NCT05367089","phase":"PHASE3","title":"The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms","status":"RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2022-08-22","conditions":"Candidiasis, Vulvovaginal, Recurrent Candidiasis of Vagina","enrollment":252},{"nctId":"NCT05661591","phase":"PHASE1","title":"Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-02-28","conditions":"Malignant Tumor","enrollment":18},{"nctId":"NCT00075803","phase":"PHASE3","title":"Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2003-11","conditions":"Lymphoma, Infection, Leukemia","enrollment":600},{"nctId":"NCT04933682","phase":"PHASE1","title":"Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-06-23","conditions":"Healthy","enrollment":16},{"nctId":"NCT04734405","phase":"PHASE2, PHASE3","title":"A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)","status":"UNKNOWN","sponsor":"ProFem GmbH","startDate":"2019-10-01","conditions":"Recurrent Vulvovaginal Candidiasis","enrollment":432},{"nctId":"NCT05059145","phase":"PHASE2","title":"A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2022-04-27","conditions":"Candidiasis, Vulvovaginal","enrollment":60},{"nctId":"NCT03840616","phase":"PHASE3","title":"Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections","status":"COMPLETED","sponsor":"Mycovia Pharmaceuticals Inc.","startDate":"2019-03-13","conditions":"Recurrent Vulvovaginal Candidiasis","enrollment":219},{"nctId":"NCT05140096","phase":"PHASE1","title":"A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2020-01-03","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT04850651","phase":"PHASE1","title":"Effect of Fluconazole on the Pharmacokinetics of Pyrotinib in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-16","conditions":"Healthy Subjects","enrollment":18},{"nctId":"NCT04956419","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Acute Vulvovaginal Candidiasis","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-24","conditions":"Acute Vulvovaginal Candidiasis","enrollment":322},{"nctId":"NCT04809649","phase":"PHASE2","title":"SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole","status":"WITHDRAWN","sponsor":"George R Thompson","startDate":"2021-05-15","conditions":"Coccidioidomycosis, Valley Fever","enrollment":""},{"nctId":"NCT03621072","phase":"PHASE1","title":"Bioequivalence (BE) Study Comparing Fluconazole 150mg Capsule Manufactured in China and in France","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-06-03","conditions":"Bioequivalence","enrollment":36},{"nctId":"NCT03821480","phase":"PHASE1","title":"Diflucan Bioequivalence Study For Transferring The Manufacture","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-01-28","conditions":"Bioequivalence","enrollment":28},{"nctId":"NCT03939273","phase":"NA","title":"The Effects of Gut Micribiota Disruption on the Immune Response After Open Heart Surgery","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-03","conditions":"Systemic Inflammatory Response Syndrome, Postoperative Shock, Coronary Artery Disease","enrollment":80},{"nctId":"NCT02734862","phase":"PHASE2","title":"CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension","status":"COMPLETED","sponsor":"Cidara Therapeutics Inc.","startDate":"2016-07-26","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":207},{"nctId":"NCT04626258","phase":"PHASE4","title":"Fluconazol Versus Medical Honey in the Treatment of Recurrent Vulvovaginal Candidiasis","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2021-03-01","conditions":"Candidiasis, Vulvovaginal, Recurrent Candidiasis of Vagina","enrollment":252},{"nctId":"NCT04621253","phase":"PHASE1","title":"Inhibition Metamizole 2020","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-04-29","conditions":"Drug-drug Interaction","enrollment":12},{"nctId":"NCT03942029","phase":"PHASE1","title":"A Drug Interaction Study of LY3154207 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-06-21","conditions":"Healthy","enrollment":36},{"nctId":"NCT02663674","phase":"PHASE4","title":"Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-29","conditions":"Coccidioidomycosis","enrollment":72},{"nctId":"NCT03929861","phase":"PHASE1","title":"Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-07-31","conditions":"Pharmacology, Clinical","enrollment":26},{"nctId":"NCT01354314","phase":"PHASE1, PHASE2","title":"Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2010-11","conditions":"HIV Associated Neurocognitive Disorder","enrollment":45},{"nctId":"NCT00811928","phase":"PHASE3","title":"Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-11","conditions":"Leukopenia","enrollment":252},{"nctId":"NCT02997059","phase":"PHASE2","title":"Effect of Fluconazole on the Levels of ASCA After Surgical Resection for Crohn's Disease.","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2008-07","conditions":"Crohn's Disease Aggravated","enrollment":35},{"nctId":"NCT01953744","phase":"PHASE3","title":"High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus","status":"TERMINATED","sponsor":"Hospital Universitário Professor Edgard Santos","startDate":"2014-02","conditions":"Cutaneous Leishmaniasis","enrollment":53},{"nctId":"NCT02093728","phase":"PHASE1","title":"To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-04","conditions":"Solid Tumours","enrollment":26},{"nctId":"NCT01153724","phase":"PHASE1","title":"Relative Bioavailability of Olodaterol and Fluconazole","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-05","conditions":"Healthy, Pulmonary Disease, Chronic Obstructive","enrollment":35},{"nctId":"NCT00860275","phase":"PHASE1","title":"Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-04","conditions":"Alzheimer Disease","enrollment":30},{"nctId":"NCT00936182","phase":"NA","title":"Study of Fluconazole in Children With Autism Spectrum Disorder","status":"UNKNOWN","sponsor":"The Center for Autism and Related Disorders","startDate":"2009-07","conditions":"Autism Spectrum Disorder","enrollment":50},{"nctId":"NCT00353561","phase":"PHASE3","title":"Diabetes Mellitus and Vulvovaginal Candidiasis","status":"COMPLETED","sponsor":"Indian Council of Medical Research","startDate":"2004-06","conditions":"Diabetes Mellitus, Vulvovaginal Candidiasis","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fluconazole capsule","genericName":"Fluconazole capsule","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Candidiasis (oropharyngeal, esophageal, vaginal, and systemic), Cryptococcal meningitis, Fungal prophylaxis in immunocompromised patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}